Novocure (NVCR): FDA Approves Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. SMCI
8. RTX
9. S
10. COF

Go back to Novocure (NVCR): FDA Approves Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer

H.C. Wainwright Upgrades NovoCure Ltd. (NVCR) to Buy

October 16, 2024 6:06 AM EDT

H.C. Wainwright analyst Emily Bodnar upgraded NovoCure Ltd. (NASDAQ: NVCR) from Neutral to Buy with a price target of $30.00.

The analyst comments "Optune Lua receives FDA approval with favorable label based on the LUNAR Phase 3 study. Yesterday after market close, Novocure announced that the FDA has approved Optune Lua for the treatment of metastatic NSCLC for use concurrently with PD-(L)1 inhibitors or docetaxel in patients who have progressed on or after a platinum based regimen. The approval was based on the Phase 3 LUNAR study which demonstrated that there was a 3.3... More